布地奈德雾化混悬液雾化吸入治疗急性发作性支气管哮喘的疗效观察

摘要

OBJECTIVE:To probe into the efficacy of budesonide nebulising suspension in aerosol inhalation in treatment of acute paroxysmal bronchial asthma and the effects on interleukin (IL) 2,IL-4,IL-6,IL-8,IL-12,IL-13,IL-25 and tumor necrosis factor alpha (TNF-α).METHODS:280 patients with acute onset of bronchial asthma admitted from Jan.2014 to Jan.2017 were extracted to be divided into observation group and control group via the random number table,with 140 cases in each.The control group was given conventional treatment,while the observation group additionally received budesonide nebulising suspension in aerosol inhalation based on the control group.The changes of IL-2,IL-4,IL-6,IL-8,IL-12,IL-13,IL-25 and TNF-α level of two groups were observed.RESULTS:After treatment,the total effective rate of observation group was 96.43％ (135/140),significantly higher than that of control group [82.86％ (116/140)],with statistically significant difference (P ＜ 0.05).The IL-2,IL-4,IL-6,IL-8,IL-12,IL-13,IL-25 and TNF-α level of two groups had been improved significantly compared with before treatment,and the observation group was better than the control group,with statistically significant difference (P ＜ 0.05).CONCLUSIONS:The efficacy of budesonide nebulising suspension in aerosol inhalation in treatment of acute paroxysmal bronchial asthma is remarkable,which can effectively improve patients' clinical symptoms,regulate the immune function and reduce the inflammatory reaction.%目的:探讨布地奈德雾化混悬液雾化吸入治疗急性发作性支气管哮喘的疗效及对白细胞介素(IL)2、IL-4、IL-6、IL-8、IL-12、IL-13、IL-25、肿瘤坏死因子α(TNF-α)水平的影响.方法:选择2014年1月-2017年1月收治的急性发作性支气管哮喘患者280例作为研究对象,按随机数字表法分为观察组和对照组,每组140例.对照组患者给予常规治疗,观察组患者在对照组基础上给予布地奈德雾化混悬液雾化吸入,观察两组患者的治疗效果及治疗前后IL-2、IL-4、IL-6、IL-8、IL-12、IL-13、IL-25和TNF-α水平变化情况.结果:治疗后,观察组患者的总有效率为96.43％ (135/140),明显高于对照组的82.86％ (116/140),差异有统计学意义(P＜0.05);两组患者的IL-2、IL-4、IL-6、IL-8、IL-12、IL-13、IL-25及TNF-α等指标水平均较治疗前明显改善,且观察组患者改善程度明显优于对照组,差异均有统计学意义(P＜0.05).结论:布地奈德雾化混悬液雾化吸入治疗急性发作性支气管哮喘效果较好,可显著改善患者临床症状,调节免疫功能,减轻炎症反应.